SP-101

AssetAlso SP-101 and doxorubicin Cohort 1

AAV gene therapy candidate designed to deliver CFTR for cystic fibrosis

Stage: Phase 1
Modality: Gene therapy
Target: CFTR; 1
Indication: 1,324
Trials: 1
Developer

Indications

1

Cystic fibrosis
Phase 1, Recruiting, NCT06526923, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Trials1,324
Evidence for its targets2
Competitors6
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 2 sources